These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8791009)

  • 21. Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways.
    Sreedharan SP; Patel DR; Xia M; Ichikawa S; Goetzl EJ
    Biochem Biophys Res Commun; 1994 Aug; 203(1):141-8. PubMed ID: 8074647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.
    Svoboda M; Tastenoy M; Van Rampelbergh J; Goossens JF; De Neef P; Waelbroeck M; Robberecht P
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1617-24. PubMed ID: 7811244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.
    Du K; Nicole P; Couvineau A; Laburthe M
    Biochem Biophys Res Commun; 1997 Jan; 230(2):289-92. PubMed ID: 9016768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M; Couvineau A; Rouyer-Fessard C
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of a CHO cell clone stably expressing the recombinant human VIP-1 receptor.
    Gaudin P; Couvineau A; Maoret JJ; Rouyer-Fessard C; Laburthe M
    Ann N Y Acad Sci; 1996 Dec; 805():570-3. PubMed ID: 8993441
    [No Abstract]   [Full Text] [Related]  

  • 26. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains.
    Couvineau A; Rouyer-Fessard C; Darmoul D; Maoret JJ; Carrero I; Ogier-Denis E; Laburthe M
    Biochem Biophys Res Commun; 1994 Apr; 200(2):769-76. PubMed ID: 8179610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
    Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
    Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor.
    Gagnon AW; Aiyar N; Elshourbagy NA
    Cell Signal; 1994 Mar; 6(3):321-33. PubMed ID: 7917790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung.
    Busto R; Carrero I; Guijarro LG; Solano RM; Zapatero J; Noguerales F; Prieto JC
    Am J Physiol; 1999 Jul; 277(1):L42-8. PubMed ID: 10409229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a VIP-specific receptor in guinea pig tenia coli.
    Teng BQ; Grider JR; Murthy KS
    Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G718-25. PubMed ID: 11518684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
    Moody TW; Jensen RT; Fridkin M; Gozes I
    J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of high affinity selective VIP1 receptor agonists.
    Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(10):1539-45. PubMed ID: 9437714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional characterization of a receptor for vasoactive-intestinal-peptide-related peptides in cultured dermal melanophores from Xenopus laevis.
    Marotti LA; Jayawickreme CK; Lerner MR
    Pigment Cell Res; 1999 Apr; 12(2):89-97. PubMed ID: 10231196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of vasoactive intestinal peptide receptors in human liver.
    Rodríguez-Henche N; Rodríguez-Pena MS; Guijarro LG; Prieto JC
    Biochim Biophys Acta; 1994 Mar; 1221(2):193-8. PubMed ID: 8148398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of VIP-and helodermin-preferring receptors on rat platelets.
    Shima K; Sakakibara H; Said SI
    Regul Pept; 1996 Jul; 63(2-3):99-103. PubMed ID: 8837217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
    Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.
    Lundberg P; Lundgren I; Mukohyama H; Lehenkari PP; Horton MA; Lerner UH
    Endocrinology; 2001 Jan; 142(1):339-47. PubMed ID: 11145597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.